Mutations associated with Helicobacter pylori antimicrobial resistance in the Ecuadorian population
© 2021 The Society for Applied Microbiology..
AIMS: We described the presence of Helicobacter pylori (HP) and estimated the prevalence of primary and secondary resistance using molecular detection in gastric biopsies of Ecuadorian patients.
METHODS AND RESULTS: 66.7% (238/357) of the patients demonstrated the presence of HP using CerTest qPCR. Of these, 69.79% (104/149) were without previous HP eradication treatment and 64.42% (134/208) with prior HP eradication treatment. The mutation-associated resistance rate for clarithromycin was 33.64% (primary resistance) and 32.82% (secondary resistance), whereas that in levofloxacin the primary and secondary resistance was 37.38% and 42%, respectively. For tetracycline and rifabutin, primary and secondary resistance was 0%. Primary and secondary resistance for metronidazole and amoxicillin could not be evaluated by genotypic methods (PCR and sequencing).
CONCLUSIONS: The analysis of mutations in gyrA, 23S rRNA and 16S rRNA is useful to detect bacterial resistance as a guide for eradication therapy following failure of the first-line regimen.
SIGNIFICANCE AND IMPACT OF THE STUDY: This study carried out in an Ecuadorian population indicates that the resistance of HP to first-line antibiotics is high, which may contribute to the high rates of treatment failure, and other treatment alternatives should be considered.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:132 |
|---|---|
| Enthalten in: |
Journal of applied microbiology - 132(2022), 4 vom: 01. Apr., Seite 2694-2704 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zurita, Jeannete [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
140QMO216E |
|---|
| Anmerkungen: |
Date Completed 31.03.2022 Date Revised 01.04.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/jam.15396 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM333928644 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM333928644 | ||
| 003 | DE-627 | ||
| 005 | 20231225222647.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/jam.15396 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1113.xml |
| 035 | |a (DE-627)NLM333928644 | ||
| 035 | |a (NLM)34856035 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zurita, Jeannete |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mutations associated with Helicobacter pylori antimicrobial resistance in the Ecuadorian population |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.03.2022 | ||
| 500 | |a Date Revised 01.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 The Society for Applied Microbiology. | ||
| 520 | |a AIMS: We described the presence of Helicobacter pylori (HP) and estimated the prevalence of primary and secondary resistance using molecular detection in gastric biopsies of Ecuadorian patients | ||
| 520 | |a METHODS AND RESULTS: 66.7% (238/357) of the patients demonstrated the presence of HP using CerTest qPCR. Of these, 69.79% (104/149) were without previous HP eradication treatment and 64.42% (134/208) with prior HP eradication treatment. The mutation-associated resistance rate for clarithromycin was 33.64% (primary resistance) and 32.82% (secondary resistance), whereas that in levofloxacin the primary and secondary resistance was 37.38% and 42%, respectively. For tetracycline and rifabutin, primary and secondary resistance was 0%. Primary and secondary resistance for metronidazole and amoxicillin could not be evaluated by genotypic methods (PCR and sequencing) | ||
| 520 | |a CONCLUSIONS: The analysis of mutations in gyrA, 23S rRNA and 16S rRNA is useful to detect bacterial resistance as a guide for eradication therapy following failure of the first-line regimen | ||
| 520 | |a SIGNIFICANCE AND IMPACT OF THE STUDY: This study carried out in an Ecuadorian population indicates that the resistance of HP to first-line antibiotics is high, which may contribute to the high rates of treatment failure, and other treatment alternatives should be considered | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Helicobacter | |
| 650 | 4 | |a PCR-based diagnosis | |
| 650 | 4 | |a antibiotic resistance | |
| 650 | 4 | |a genotyping | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a RNA, Ribosomal, 16S |2 NLM | |
| 650 | 7 | |a Metronidazole |2 NLM | |
| 650 | 7 | |a 140QMO216E |2 NLM | |
| 650 | 7 | |a Amoxicillin |2 NLM | |
| 650 | 7 | |a 804826J2HU |2 NLM | |
| 700 | 1 | |a Sevillano, Gabriela |e verfasserin |4 aut | |
| 700 | 1 | |a Paz Y Miño, Ariane |e verfasserin |4 aut | |
| 700 | 1 | |a Zurita-Salinas, Camilo |e verfasserin |4 aut | |
| 700 | 1 | |a Peñaherrera, Vicente |e verfasserin |4 aut | |
| 700 | 1 | |a Echeverría, Manuel |e verfasserin |4 aut | |
| 700 | 0 | |a Helicobacter pylori Research Group |e verfasserin |4 aut | |
| 700 | 1 | |a Navarrete, Hugo |e verfasserin |4 aut | |
| 700 | 1 | |a Silva Casares, María Ángeles |e investigator |4 oth | |
| 700 | 1 | |a Orellana Narvaez, Ivonne |e investigator |4 oth | |
| 700 | 1 | |a Yépez, Juan Esteban |e investigator |4 oth | |
| 700 | 1 | |a Zaldumbide Serrano, Francisco |e investigator |4 oth | |
| 700 | 1 | |a Oviedo Valdiviezo, César |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of applied microbiology |d 1997 |g 132(2022), 4 vom: 01. Apr., Seite 2694-2704 |w (DE-627)NLM090698444 |x 1365-2672 |7 nnns |
| 773 | 1 | 8 | |g volume:132 |g year:2022 |g number:4 |g day:01 |g month:04 |g pages:2694-2704 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/jam.15396 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 132 |j 2022 |e 4 |b 01 |c 04 |h 2694-2704 | ||